• GE HealthCare third-quarter 2026 diluted EPS rose 39% to $1.36, while revenues increased 7% to $5.51 billion.
• Cash flow from operating activities climbed 53% to $907 million, including a $55 million tariff refund.
• The planned $945 million cash acquisition of SOFIE Biosciences is expected to close in the first half of 2027, pending approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261028662941) on October 28, 2026, and is solely responsible for the information contained therein.